Iradimed Company Insiders

Iradimed Management Team Effectiveness

The company has return on total asset (ROA) of 0.1441 % which means that it generated a profit of $0.1441 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.2431 %, meaning that it created $0.2431 on every $100 dollars invested by stockholders. Iradimed's management efficiency ratios could be used to measure how well Iradimed manages its routine affairs as well as how well it operates its assets and liabilities. As of February 26, 2025, Return On Tangible Assets is expected to decline to 0.17. In addition to that, Return On Capital Employed is expected to decline to 0.24. At present, Iradimed's Non Currrent Assets Other are projected to increase significantly based on the last few years of reporting. The current year's Intangible Assets is expected to grow to about 3 M, whereas Other Assets are forecasted to decline to 1.09. The current year's Common Stock Shares Outstanding is expected to grow to about 13.1 M. The current year's Net Income Applicable To Common Shares is expected to grow to about 15.5 M

Iradimed Workforce Comparison

Iradimed Profit Margins

The company has Profit Margin (PM) of 0.26 %, which maeans that even a very small decline in it revenue will erase profits resulting in a net loss. This is way below average. Similarly, it shows Operating Margin (OM) of 0.3 %, which suggests for every 100 dollars of sales, it generated a net operating income of $0.3.

Iradimed Insider Trading History

Iradimed Notable Stakeholders

The success or failure of an entity such as Iradimed often depends on how effective the management is. Iradimed management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Iradimed management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Iradimed management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.

Please note, the presentation of Iradimed's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Iradimed's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Iradimed's management manipulating its earnings.

When running Iradimed's price analysis, check to measure Iradimed's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Iradimed is operating at the current time. Most of Iradimed's value examination focuses on studying past and present price action to predict the probability of Iradimed's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Iradimed's price. Additionally, you may evaluate how the addition of Iradimed to your portfolios can decrease your overall portfolio volatility.